UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
Ryanair Profit Slumps in Q3 After Italy Antitrust Fine Despite Revenue Growth 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
Hyundai Motor Shares Slide After Trump Signals Higher U.S. Tariffs on South Korean Goods 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
RESEARCH TRIANGLE PARK, N.C., May 16, 2017 -- G1 Therapeutics, Inc., a clinical-stage oncology company, today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $15.00 per share for aggregate gross proceeds of $105,000,000. In addition, G1 Therapeutics has granted the underwriters a 30-day option to purchase up to 1,050,000 additional shares of its common stock at the initial public offering price. The shares are scheduled to begin trading on The NASDAQ Global Select Market on May 17, 2017 under the ticker symbol “GTHX.”
J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Needham & Company, LLC and Wedbush Securities Inc. are acting as co-managers for the offering.
A registration statement relating to these securities has been filed with and was declared effective by the Securities and Exchange Commission on May 16, 2017. The offering will be made only by means of a prospectus. A copy of the final prospectus relating to the offering will be filed with the Securities and Exchange Commission and may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by calling (631) 274-2806 or by faxing (631) 254-7140.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About G1 Therapeutics, Inc.
G1 Therapeutics is a clinical-stage biopharmaceutical company developing novel, small-molecule therapies that address significant unmet needs in the treatment of cancer. The company is advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications. G1 is based in Research Triangle Park, NC.
Contacts Investors: Robert Uhl Westwicke Partners 858-356-5932 [email protected] Media: Laura Bagby 6 Degrees Communications 312-448-8098 [email protected]
